Top Page
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
(2252)
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 257.25M | 104.59M | 21.60M | 2.15M | 0.00 | Gross Profit |
| 86.22M | 14.69M | 6.56M | 919.00K | 0.00 | EBIT |
| -488.75M | -975.14M | -1.10B | -610.18M | -158.43M | EBITDA |
| -413.34M | -893.36M | -1.01B | -543.84M | -160.93M | Net Income Common Stockholders |
| -642.41M | -1.01B | -1.17B | -542.69M | -261.25M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 612.23M | 507.71M | 747.96M | 1.94B | 1.50B | Total Assets |
| 1.28B | 1.43B | 1.93B | 2.79B | 1.70B | Total Debt |
| 691.33M | 560.42M | 219.95M | 204.68M | 18.88M | Net Debt |
| 79.10M | 52.71M | -528.01M | -1.74B | -1.48B | Total Liabilities |
| 1.02B | 926.15M | 522.25M | 401.73M | 262.90M | Stockholders Equity |
| 278.20M | 519.48M | 1.42B | 2.39B | 1.44B |
| Cash Flow | Free Cash Flow | |||
| 0.00 | -634.30M | -1.09B | -674.47M | -118.05M | Operating Cash Flow |
| 0.00 | -567.84M | -898.48M | -540.49M | -103.04M | Investing Cash Flow |
| 0.00 | -58.38M | -267.82M | -396.57M | -15.01M | Financing Cash Flow |
| 0.00 | 385.68M | -27.95M | 1.39B | 1.56B |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $113.92B | 31.58 | 8.17% | ― | 7.52% | -1.92% | |
65 Neutral | HK$69.10B | 15.08 | 6.22% | 1.77% | -2.82% | 11.93% | |
64 Neutral | $20.25B | 13.99 | 6.68% | 4.72% | 0.24% | -31.74% | |
62 Neutral | HK$3.78B | 21.21 | 4.47% | ― | -9.75% | ― | |
55 Neutral | HK$86.03B | ― | -8.98% | ― | -54.66% | -123.11% | |
54 Neutral | $5.37B | 3.26 | -45.10% | 3.30% | 16.81% | 0.02% | |
44 Neutral | HK$17.29B | ― | -160.49% | ― | 141.72% | 38.39% |
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events
Shanghai MicroPort MedBot (Group) Co., Ltd. announced the resignation of Mr. Chen Xinxing as a non-executive director and audit committee member, effective April 30, 2025, as he intends to focus on other work commitments. The board expressed gratitude for his contributions and confirmed no disagreements with the board. Following his departure, the audit committee will be restructured to include Mr. Chung Wai Man, Dr. Li Minghua, and Mr. Yao Haisong, with Mr. Chung continuing as chairperson.
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is significant as it outlines the leadership structure and strategic direction of the company, which could influence its operations and market positioning within the medical technology industry.
Shanghai MicroPort MedBot has achieved a significant milestone with the approval of its Toumai Remote laparoscopic surgical robot by the National Medical Products Administration of China. This approval marks the world’s first for full-department application in remote surgery, enhancing the company’s product portfolio and positioning it as a leader in the global remote surgery field. The Toumai Remote system, compatible with multiple communication networks, has been instrumental in performing nearly 400 remote surgeries across various countries, showcasing its innovative capabilities and establishing numerous national and world records.
Shanghai MicroPort MedBot (Group) Co., Ltd. has proposed an amendment to its Articles of Association to increase the number of board seats from eight to nine, which will be considered at the upcoming annual general meeting. Additionally, the company has nominated Mr. Liu Yu as an executive director, pending shareholder approval. Mr. Liu brings over 30 years of experience in the pharmaceuticals and medical devices industry, having held significant roles in various companies, which could enhance the company’s strategic direction and operational efficiency.
Shanghai MicroPort MedBot reported a significant revenue increase of 146% for the year ended December 31, 2024, reaching RMB257.2 million, driven by strong sales growth in domestic and overseas markets. Despite a net loss of RMB647.1 million, the company improved its financial performance by reducing its net loss by 36.8% compared to the previous year, attributed to increased gross profit, reduced R&D costs, and decreased administrative expenses. The company also successfully reduced its net free cash outflow by 42%, reflecting strategic focus and efficiency measures, although these gains were partially offset by an impairment loss on an overseas investment.
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced that its board of directors will hold a meeting on March 27, 2025, to discuss and approve the final results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend and address other business matters, which could impact the company’s financial strategy and shareholder returns.
Shanghai MicroPort MedBot (Group) Co., Ltd. has announced an expected revenue growth of 145% to 155% for the year ending December 31, 2024, driven by strong sales in both domestic and international markets. Despite this growth, the company anticipates an adjusted net loss of RMB435 million to RMB521 million, a significant reduction from the previous year’s loss, due to increased revenue and decreased operating expenses.
Shanghai MicroPort MedBot has received approval from the National Medical Products Administration of China for its Toumai Single-arm and Single-port Laparoscopic Surgical Robot. This approval marks a significant milestone in the company’s business development, enhancing its product portfolio and market competitiveness. The Toumai Single-arm robot, characterized by its unique single-arm structure and sophisticated design, offers clinical advantages such as smaller wounds and less pain, thus improving post-operative aesthetics. This development is expected to strengthen the company’s position in both the domestic and international markets.